Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RENAISSANCE

Financiado

Advanced biomarker discovery for earlier diagnosis and improved prognosis of NAF...

Advanced biomarker discovery for earlier diagnosis and improved prognosis of NAFLD stages via high resolution mass spectrometry. Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of nearly 25% i.e., affects one quarter of the adult population. Early phase NAFLD is reversible and can be treated, but it may progress towards life-threatening st... ver más

30/06/2025

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

Masarykova univerzita No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-16

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... ExpectedOutcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MSC...

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

150.44K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RENAISSANCE Advanced biomarker discovery for earlier diagnosis and impro... 150K€ Cerrado

SAF2017-88041-R IDENTIFICACION Y VALIDACION DE BIOMARCADORES METABOLOMICOS N... 223K€ Cerrado

PID2021-125394OA-I00 ESTADIFICACION NO INVASIVA DE LA ESTETATOHEPATITIS NO ALCOHO... 121K€ Cerrado

IDENTIFICACIÓN DE BIOMARCADORES DE ESTEATOSIS... IDENTIFICACIÓN DE BIOMARCADORES DE ESTEATOSIS HEPÁTICA NO-AL... 44K€ Cerrado

M4Liver Application of Metal-organic frameworks synthesized by Micro... 188K€ Cerrado

EQC2021-007112-P CROMATOGRAFÍA DE LÍQUIDOS ACOPLADA A ESPECTROMETRÍA DE MASAS... 873K€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2023-05-16
Fecha Fin: 2025-06-30

Líder del proyecto

Masarykova univerzita No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of nearly 25% i.e., affects one quarter of the adult population. Early phase NAFLD is reversible and can be treated, but it may progress towards life-threatening stages such as non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). The conventional diagnosis of NAFLD stages requires liver biopsy and is time-consuming and costly and there is an urgent need to identify biomarkers that can be applied in routine clinical settings, such as through blood-based testing. The identification of blood biomarkers would support earlier diagnosis and improved assessment of prognosis, ultimately supporting preventive/intervention measures to avoid progression to late stage liver disease and thus saving lives. In RENAISSANCE, a state-of-the-art liquid chromatography-high resolution mass spectrometry (LC-HRMS) metabolomics screening will be conducted upon the blood and blood-derived exosomes of a unique deeply phenotyped cohort of NAFLD patients for molecular biomarker discovery. Notably, exosome analysis shows promise for the identification of novel disease signatures but has yet to be applied to characterize NAFLD, providing high potential for the identification of new diagnostic/prognostic biomarkers for NAFLD. Furthermore, the LC-HRMS screen will be supported via targeted assays of redox metabolites and protein markers of acute inflammation. The integration of non-target and target data will provide insight into the underlying mechanisms of disease progression and further knowledge about potential causative factors of NAFLD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores